Ovarian cancer is the most lethal gynecological cancer, mainly because of the advanced stage of the disease at diagnosis, with recent research investigating novel targets and agents into the clinical practice, with the aim to improve prognosis and quality of life. Angiogenesis is a significant target for ovarian cancer therapy. Areas covered in this review include the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in ovarian cancer patients. These therapeutic strategies comprise monoclonal antibodies and tyrosine kinase inhibitors. These drugs have as molecular targets such as vascular endothelial growth factor (VEGF), VEGF receptor, platelet-derived growth factor, fibroblast growth factor, angiopoietin and Ephrin type-A receptor 2. The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important pathways, but the heterogeneity of ovarian cancer biology indicates that there is no predominant defect. This review attempts to discuss progress till date in tackling a more general target applicable to ovarian cancer angiogenesis.

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer / Tomao, Federica; Papa, Anselmo; Rossi, Luigi; Caruso, Davide; Zoratto, Federica; BENEDETTI PANICI, Pierluigi; Tomao, Silverio. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - ELETTRONICO. - 23:1(2014), pp. 37-53. [10.1517/13543784.2013.839657]

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.

TOMAO, FEDERICA;PAPA, ANSELMO;ROSSI, Luigi;CARUSO, DAVIDE;ZORATTO, federica;BENEDETTI PANICI, PIERLUIGI;TOMAO, SILVERIO
2014

Abstract

Ovarian cancer is the most lethal gynecological cancer, mainly because of the advanced stage of the disease at diagnosis, with recent research investigating novel targets and agents into the clinical practice, with the aim to improve prognosis and quality of life. Angiogenesis is a significant target for ovarian cancer therapy. Areas covered in this review include the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in ovarian cancer patients. These therapeutic strategies comprise monoclonal antibodies and tyrosine kinase inhibitors. These drugs have as molecular targets such as vascular endothelial growth factor (VEGF), VEGF receptor, platelet-derived growth factor, fibroblast growth factor, angiopoietin and Ephrin type-A receptor 2. The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important pathways, but the heterogeneity of ovarian cancer biology indicates that there is no predominant defect. This review attempts to discuss progress till date in tackling a more general target applicable to ovarian cancer angiogenesis.
tyrosine kinase inhibitors; aflibercept; vascular endothelial growth factor; ovarian cancer; epithelial ovarian cancer; bevacizumab; angiogenesis; chemotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer / Tomao, Federica; Papa, Anselmo; Rossi, Luigi; Caruso, Davide; Zoratto, Federica; BENEDETTI PANICI, Pierluigi; Tomao, Silverio. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - ELETTRONICO. - 23:1(2014), pp. 37-53. [10.1517/13543784.2013.839657]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/525924
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact